AN Unusual case of osteoblastoma in an elderly female: A case report and a review

Abstract

Osteoblastoma is a rare entity encountered as a benign osseous tumor with the propensity of occurrence towards the vertebral column and long bones. Commonly occurs in young middle-aged males with mandible as a site of predilection in the facial skeleton. Differential diagnosis of osteoblastoma holds a challenge in attaining a final diagnosis. Osteoid osteoma, cementoblastoma, osteosarcoma, aggressive fibrous dysplasia, and ossifying fibroma share a similar clinical behavior, radiological and histological behavior. This article aims to report a case of osteoblastoma of an aggressive variety appearing in the maxilla. It aims to gain a better understanding of the clinical, histological, radiological, and differential diagnosis of osteoblastoma. A review of English language literature in 2006 revealed 43 previously reported cases of osteoblastoma appearing in the maxilla and mandible since 1967. 16 cases including this one are added to the previous well-documented review of literature by Jones where he included additional 24 cases to the previously reported 43 cases. Brief discussion and review on treatment modalities are analyzed.

Voyage of Measurable Residual Disease Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry

“…A few publications in the literature correlated the log reduction in MRD assessment with survival where researchers studied MRD level as a continuous variable determined by flow cytometry and demonstrated survival benefits in MM patients per log depletion in MRD. 54 55 Likewise, our group also demonstrated that gradual fall in MRD levels from 0.1 to 0.001% is predictive of superior survival outcomes 35 ( Fig. 4 ).…”

“…Thus, using clonal PC as numerator and total PC as denominator, we defined NPCI, as NPCI = clonal PC/total PC. 35…”

“…Thus, recently we demonstrated the utility of NPCI, that is, the percentage of clonal APC of the total PC in for MRD evaluation as a parameter to document MRD. 35 Since both neoplastic and NPC are proportionately reduced in a hemodiluted BMA, NPCI may prove to be a better parameter to assess MRD and may be explored further in larger cohorts.…”

“…Recently, we too have demonstrated that day 100 post-transplant MRD positive status is associated with poor survival outcome compared to MRD negative status with progressive worsening of both PFS and OS with increase in MRD levels. 35…”